Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by LMR Partners LLP

LMR Partners LLP reduced its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 82.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,901 shares of the biopharmaceutical company's stock after selling 55,588 shares during the quarter. LMR Partners LLP's holdings in Alnylam Pharmaceuticals were worth $2,800,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC lifted its position in Alnylam Pharmaceuticals by 0.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company's stock valued at $1,532,000 after purchasing an additional 58 shares in the last quarter. Harbor Capital Advisors Inc. lifted its holdings in Alnylam Pharmaceuticals by 2.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 2,650 shares of the biopharmaceutical company's stock worth $624,000 after buying an additional 63 shares during the period. Pallas Capital Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 2.6% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,408 shares of the biopharmaceutical company's stock worth $802,000 after purchasing an additional 87 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of Alnylam Pharmaceuticals by 13.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock worth $4,687,000 after purchasing an additional 2,285 shares in the last quarter. Finally, Park Avenue Securities LLC increased its position in shares of Alnylam Pharmaceuticals by 64.8% in the 4th quarter. Park Avenue Securities LLC now owns 1,368 shares of the biopharmaceutical company's stock valued at $322,000 after acquiring an additional 538 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the sale, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the completion of the sale, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,017,271.63. This represents a 11.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have commented on ALNY shares. Redburn Atlantic started coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They issued a "buy" rating and a $353.00 price target on the stock. Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a report on Friday, March 21st. UBS Group lifted their target price on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Needham & Company LLC reaffirmed a "buy" rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Finally, JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $280.00 to $328.00 in a research report on Monday, March 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $319.17.

Alnylam Pharmaceuticals Trading Up 0.7%

Shares of ALNY traded up $1.91 on Friday, hitting $285.31. 1,193,496 shares of the stock traded hands, compared to its average volume of 910,177. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The firm has a market capitalization of $37.20 billion, a P/E ratio of -131.48 and a beta of 0.17. The stock's 50 day moving average is $253.73 and its two-hundred day moving average is $253.77. Alnylam Pharmaceuticals, Inc. has a 1 year low of $146.79 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. The company's revenue for the quarter was up 20.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.16) earnings per share. As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.